{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:40:40Z","timestamp":1764996040077,"version":"3.46.0"},"reference-count":42,"publisher":"Japanese Society of Toxicology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2025]]},"DOI":"10.2131\/jts.50.691","type":"journal-article","created":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T22:06:58Z","timestamp":1764540418000},"page":"691-705","source":"Crossref","is-referenced-by-count":0,"title":["Rodent-specific induction of cholestasis and cholangioma through the reduction of bile salt export pump by bardoxolone methyl"],"prefix":"10.2131","volume":"50","author":[{"given":"Hironori","family":"Otsuki","sequence":"first","affiliation":[{"name":"Kyowa Kirin Co., Ltd."},{"name":"Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Araki","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Takami","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Inomata","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Hiura","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichiro","family":"Nan-ya","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Yoshinari","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"Bj\u00f6rnsson, E. and Olsson, R. (2005): Outcome and prognostic markers in severe drug-induced liver disease. Hepatology, <b>42<\/b>, 481-489.","DOI":"10.1002\/hep.20800"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Chin, M.P., Bakris, G.L., Block, G.A., Chertow, G.M., Goldsberry, A., Inker, L.A., Heerspink, H.J., O\u2019Grady, M., Pergola, P.E., Wanner, C., Warnock, D.G. and Meyer, C.J. (2018): Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. Am. J. Nephrol., <b>47<\/b>, 40-47.","DOI":"10.1159\/000486398"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Dinkova-Kostova, A.T., Liby, K.T., Stephenson, K.K., Holtzclaw, W.D., Gao, X., Suh, N., Williams, C., Risingsong, R., Honda, T., Gribble, G.W., Sporn, M.B. and Talalay, P. (2005): Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc. Natl. Acad. Sci. USA, <b>102<\/b>, 4584-4589.","DOI":"10.1073\/pnas.0500815102"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Gomez-Ospina, N., Potter, C.J., Xiao, R., Manickam, K., Kim, M.S., Kim, K.H., Shneider, B.L., Picarsic, J.L., Jacobson, T.A., Zhang, J., He, W., Liu, P., Knisely, A.S., Finegold, M.J., Muzny, D.M., Boerwinkle, E., Lupski, J.R., Plon, S.E., Gibbs, R.A., Eng, C.M., Yang, Y., Washington, G.C., Porteus, M.H., Berquist, W.E., Kambham, N., Singh, R.J., Xia, F., Enns, G.M. and Moore, D.D. (2016): Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat. Commun., <b>7<\/b>, 10713. Nature Publishing Group.","DOI":"10.1038\/ncomms10713"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Heathcote, E.J. (2007): Diagnosis and management of cholestatic liver disease. Clin. Gastroenterol. Hepatol., <b>5<\/b>, 776-782.","DOI":"10.1016\/j.cgh.2007.05.008"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J.D. and Yamamoto, M. (1999): Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev., <b>13<\/b>, 76-86.","DOI":"10.1101\/gad.13.1.76"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Jiang, L., Zhang, H., Xiao, D., Wei, H. and Chen, Y. (2021): Farnesoid X receptor (FXR): structures and ligands. Comput. Struct. Biotechnol. J., <b>19<\/b>, 2148-2159. The Author(s)","DOI":"10.1016\/j.csbj.2021.04.029"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Kad\u0131o\u011flu, E., Tek\u015fen, Y., Ko\u00e7ak, C. and Ko\u00e7ak, F.E. (2021): Beneficial effects of bardoxolone methyl, an Nrf2 activator, on crush-related acute kidney injury in rats. Eur. J. Trauma Emerg. Surg., <b>47<\/b>, 241-250. Springer Berlin Heidelberg.","DOI":"10.1007\/s00068-019-01216-z"},{"key":"9","doi-asserted-by":"publisher","unstructured":"Keitel, V., Burdelski, M., Warskulat, U., K\u00fchlkamp, T., Keppler, D., H\u00e4ussinger, D. and Kubitz, R. (2005): Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology, <b>41<\/b>, 1160-1172.","DOI":"10.1002\/hep.20682"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Knisely, A.S., Strautnieks, S.S., Meier, Y., Stieger, B., Byrne, J.A., Portmann, B.C., Bull, L.N., Pawlikowska, L., Bilezik\u00e7i, B., Oz\u00e7ay, F., L\u00e1szl\u00f3, A., Tiszlavicz, L., Moore, L., Raftos, J., Arnell, H., Fischler, B., N\u00e9meth, A., Papadogiannakis, N., Cielecka-Kuszyk, J., Jankowska, I., Paw\u0142owska, J., Mel\u00edn-Aldana, H., Emerick, K.M., Whitington, P.F., Mieli-Vergani, G. and Thompson, R.J. (2006): Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology, <b>44<\/b>, 478-486.","DOI":"10.1002\/hep.21287"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Kong, B., Zhu, Y., Li, G., Williams, J.A., Buckley, K., Tawfik, O., Luyendyk, J.P. and Guo, G.L. (2016): Mice with hepatocyte-specific FXR deficiency are resistant to spontaneous but susceptible to cholic acid-induced hepatocarcinogenesis. Am. J. Physiol. Gastrointest. Liver Physiol., <b>310<\/b>, G295-G302.","DOI":"10.1152\/ajpgi.00134.2015"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Lesage, G., Glaser, S., Regulation, A.G., Lesage, G., Glaser, S. and Alpini, G. (2001): Regulation of cholangiocyte proliferation. 73-80.","DOI":"10.1034\/j.1600-0676.2001.021002073.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Lewis, J.H. (2000): DRUG-INDUCED LIVER DISEASE. Med. Clin. North Am., <b>84<\/b>, 1275-1311.","DOI":"10.1016\/S0025-7125(05)70287-X"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Lewis, J.H., Jadoul, M., Block, G.A., Chin, M.P., Ferguson, D.A., Goldsberry, A., Meyer, C.J., O\u2019Grady, M., Pergola, P.E., Reisman, S.A., Wigley, W.C. and Chertow, G.M. (2021): Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD. Clin. Transl. Sci., <b>14<\/b>, 299-309.","DOI":"10.1111\/cts.12868"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Lin, C., Wen, X. and Sun, H. (2016): Oleanolic acid derivatives for pharmaceutical use: a patent review. Expert Opin. Ther. Pat., <b>26<\/b>, 643-655. Taylor &amp; Francis.","DOI":"10.1080\/13543776.2016.1182988"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Lipton, S. and Satoh, T. (2017): Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate. F1000 Res., <b>6<\/b>, 1-10.","DOI":"10.12688\/f1000research.12111.1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Liu, W. and Wong, C. (2010): Oleanolic acid is a selective farnesoid X receptor modulator. Phytother. Res., <b>24<\/b>, 369-373.","DOI":"10.1002\/ptr.2948"},{"key":"18","doi-asserted-by":"publisher","unstructured":"Lu, Y.F., Wan, X.L., Xu, Y. and Liu, J. (2013): Repeated oral administration of oleanolic acid produces cholestatic liver injury in mice. Molecules, <b>18<\/b>, 3060-3071.","DOI":"10.3390\/molecules18033060"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Nangaku, M., Kanda, H., Takama, H., Ichikawa, T., Hase, H. and Akizawa, T. (2020): Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study). Kidney Int. Rep., <b>5<\/b>, 879-890. Elsevier Inc.","DOI":"10.1016\/j.ekir.2020.03.030"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Okada, K., Shoda, J., Taguchi, K., Maher, J.M., Ishizaki, K., Inoue, Y., Ohtsuki, M., Goto, N., Takeda, K., Utsunomiya, H., Oda, K., Warabi, E., Ishii, T., Osaka, K., Hyodo, I. and Yamamoto, M. (2008): Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. Am. J. Physiol. Gastrointest. Liver Physiol., <b>295<\/b>, G735-G747.","DOI":"10.1152\/ajpgi.90321.2008"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Okada, K., Shoda, J., Taguchi, K., Maher, J.M., Ishizaki, K., Inoue, Y., Ohtsuki, M., Goto, N., Sugimoto, H., Utsunomiya, H., Oda, K., Warabi, E., Ishii, T. and Yamamoto, M. (2009): Nrf2 counteracts cholestatic liver injury via stimulation of hepatic defense systems. Biochem. Biophys. Res. Commun., <b>389<\/b>, 431-436. Elsevier Inc.","DOI":"10.1016\/j.bbrc.2009.08.156"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Okada, K., Shoda, J., Kano, M., Suzuki, S., Ohtake, N., Yamamoto, M., Takahashi, H., Utsunomiya, H., Oda, K., Sato, K., Watanabe, A., Ishii, T., Itoh, K., Yamamoto, M., Yokoi, T., Yoshizato, K., Sugiyama, Y. and Suzuki, H. (2022): Inchinkoto, a herbal medicine, and its ingredients dually exert Mrp2 \/ MRP2- mediated choleresis and Nrf2-mediated antioxidative action in rat livers. 1450\u20131463.","DOI":"10.1152\/ajpgi.00302.2006"},{"key":"23","doi-asserted-by":"publisher","unstructured":"Padda, M.S., Sanchez, M., Akhtar, A.J. and Boyer, J.L. (2011): Drug-induced cholestasis. Hepatology, <b>53<\/b>, 1377-1387.","DOI":"10.1002\/hep.24229"},{"key":"24","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Pineda, S.I., Bayl\u00f3n-Pacheco, L., Esp\u00edritu-Gordillo, P., Tsutsumi, V. and Rosales-Encina, J.L. (2021): Effect of bile acids on the expression of MRP3 and MRP4: an In vitro study in HepG2 cell line. Ann. Hepatol., <b>24<\/b>, 100325.","DOI":"10.1016\/j.aohep.2021.100325"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Pergola, P.E., Raskin, P., Toto, R.D., Meyer, C.J., Huff, J.W., Grossman, E.B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., Wittes, J. and Warnock, D.G.; BEAM Study Investigators. (2011a): Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med., <b>365<\/b>, 327-336.","DOI":"10.1056\/NEJMoa1105351"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Pergola, P.E., Krauth, M., Huff, J.W., Ferguson, D.A., Ruiz, S., Meyer, C.J. and Warnock, D.G. (2011b): Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am. J. Nephrol., <b>33<\/b>, 469-476.","DOI":"10.1159\/000327599"},{"key":"27","doi-asserted-by":"publisher","unstructured":"Razumilava, N. and Gores, G.J. (2014): Cholangiocarcinoma. Lancet, <b>383<\/b>, 2168-2179.","DOI":"10.1016\/S0140-6736(13)61903-0"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Reisman, S.A., Csanaky, I.L., Yeager, R.L. and Klaassen, C.D. (2009): Nrf2 activation enhances biliary excretion of sulfobromophthalein by inducing glutathione-S-transferase activity. Toxicol. Sci., <b>109<\/b>, 24-30.","DOI":"10.1093\/toxsci\/kfp045"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Reisman, S.A., Chertow, G.M., Hebbar, S., Vaziri, N.D., Ward, K.W. and Meyer, C.J. (2012): Bardoxolone methyl decreases megalin and activates nrf2 in the kidney. J. Am. Soc. Nephrol., <b>23<\/b>, 1663-1673.","DOI":"10.1681\/ASN.2012050457"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Rojas-Rivera, J., Ortiz, A. and Egido, J. (2012): Antioxidants in kidney diseases: the impact of bardoxolone methyl. Int. J. Nephrol., <b>2012<\/b>, 321714.","DOI":"10.1155\/2012\/321714"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Scheimann, A.O., Strautnieks, S.S., Knisely, A.S., Byrne, J.A., Thompson, R.J. and Finegold, M.J. (2007): Mutations in bile salt export pump (ABCB11) in two children with progressive familial intrahepatic cholestasis and cholangiocarcinoma. J. Pediatr., <b>150<\/b>, 556-559.","DOI":"10.1016\/j.jpeds.2007.02.030"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Shelton, L.M., Lister, A., Walsh, J., Jenkins, R.E., Wong, M.H., Rowe, C., Ricci, E., Ressel, L., Fang, Y., Demougin, P., Vukojevic, V., O\u2019Neill, P.M., Goldring, C.E., Kitteringham, N.R., Park, B.K., Odermatt, A. and Copple, I.M. (2015): Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney. Kidney Int., <b>88<\/b>, 1261-1273.","DOI":"10.1038\/ki.2015.286"},{"key":"33","doi-asserted-by":"publisher","unstructured":"Sinal, C.J., Tohkin, M., Miyata, M., Ward, J.M., Lambert, G. and Gonzalez, F.J. (2000): Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis. Cell, <b>102<\/b>, 731-744.","DOI":"10.1016\/S0092-8674(00)00062-3"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Stieger, B. (2010): Role of the bile salt export pump, BSEP, in acquired forms of cholestasis. Drug Metab. Rev., <b>42<\/b>, 437-445.","DOI":"10.3109\/03602530903492004"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Swift, B., Pfeifer, N.D. and Brouwer, K.L. (2010): Sandwich-cultured hepatocytes: an <i>in vitro<\/i> model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab. Rev., <b>42<\/b>, 446-471.","DOI":"10.3109\/03602530903491881"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Taguchi, K., Maher, J.M., Suzuki, T., Kawatani, Y., Motohashi, H. and Yamamoto, M. (2010): Genetic analysis of cytoprotective functions supported by graded expression of Keap1. Mol. Cell. Biol., <b>30<\/b>, 3016-3026.","DOI":"10.1128\/MCB.01591-09"},{"key":"37","doi-asserted-by":"publisher","unstructured":"Weerachayaphorn, J., Cai, S.Y., Soroka, C.J. and Boyer, J.L. (2009): Nuclear factor erythroid 2-related factor 2 is a positive regulator of human bile salt export pump expression. Hepatology, <b>50<\/b>, 1588-1596.","DOI":"10.1002\/hep.23151"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Yang, K., K\u00f6ck, K., Sedykh, A., Tropsha, A. and Brouwer, K.L. (2013): An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. J. Pharm. Sci., <b>102<\/b>, 3037-3057.","DOI":"10.1002\/jps.23584"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Yates, M.S., Tauchi, M., Katsuoka, F., Flanders, K.C., Liby, K.T., Honda, T., Gribble, G.W., Johnson, D.A., Johnson, J.A., Burton, N.C., Guilarte, T.R., Yamamoto, M., Sporn, M.B. and Kensler, T.W. (2007): Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol. Cancer Ther., <b>6<\/b>, 154-162.","DOI":"10.1158\/1535-7163.MCT-06-0516"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Yin, X., Zheng, S.S., Zhang, B.H., Zhou, Y., Chen, X.H., Ren, Z.G., Qiu, S.J. and Fan, J. (2013): Elevation of serum \u03b3-glutamyltransferase as a predictor of aggressive tumor behaviors and unfavorable prognosis in patients with intrahepatic cholangiocarcinoma: analysis of a large monocenter study. Eur. J. Gastroenterol. Hepatol., <b>25<\/b>, 1408-1414.","DOI":"10.1097\/MEG.0b013e328364130f"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Zamek-Gliszczynski, M.J., Xiong, H., Patel, N.J., Turncliff, R.Z., Pollack, G.M. and Brouwer, K.L. (2003): Pharmacokinetics of 5 (and 6)-carboxy-2\u2032,7\u2032-dichlorofluorescein and its diacetate promoiety in the liver. J. Pharmacol. Exp. Ther., <b>304<\/b>, 801-809.","DOI":"10.1124\/jpet.102.044107"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Zollner, G., Wagner, M., Moustafa, T., Fickert, P., Silbert, D., Gumhold, J., Fuchsbichler, A., Halilbasic, E., Denk, H., Marschall, H.U. and Trauner, M. (2006): Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-\u03b1\/\u03b2 in the adaptive response to bile acids. Am. J. Physiol. Gastrointest. Liver Physiol., <b>290<\/b>, G923-G932.","DOI":"10.1152\/ajpgi.00490.2005"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/50\/12\/50_691\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:07:28Z","timestamp":1764994048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/50\/12\/50_691\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.50.691","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"type":"print","value":"0388-1350"},{"type":"electronic","value":"1880-3989"}],"subject":[],"published":{"date-parts":[[2025]]}}}